Tourmaline Bio’s Post

🧬 Protein Kinase N (PKN) 🔲 Family: PKN belongs to the AGC (protein kinase A, G, and C) family of serine/threonine kinases. 🔲 Isoforms: There are three isoforms: PKN1, PKN2, and PKN3. 🔲 Activation: Activated by Rho GTPases, phospholipids, and fatty acids. 🔲 Clinical Importance ▪️Cancer: PKNs are implicated in various cancers. They regulate cell proliferation, survival, and migration, making them potential targets for cancer therapy. ▪️Cardiovascular Diseases: PKN1 and PKN2 play roles in cardiovascular health by influencing heart muscle contraction and blood vessel function. ▪️Diabetes: PKNs are involved in insulin signaling pathways, affecting glucose metabolism and insulin resistance. ▪️Neurodegenerative Diseases: PKNs have been studied for their role in neuroprotection and neuronal survival, offering potential therapeutic avenues for diseases like Alzheimer's. #ProteinKinaseN #PKN #CancerResearch #CardiovascularHealth #DiabetesResearch #NeurodegenerativeDiseases #MedicalResearch #Biochemistry Image Courtesy: Revvity (Image for illustration purpose only)

IgG4-related disease (IgG4-RD) has complex clinical manifestations ranging from fibrosis and inflammation to deregulated metabolism. The molecular mechanisms underpinning these phenotypes are unclear. To investigate the transcriptomic changes in IgG4-RD patients, we performed transcriptome profiling of B cells isolated from HCs or IgG4-RD patients by using GeneMind GenoLab M sequencer. In this study, by using IgG4-RD patient peripheral blood mononuclear cells (PBMCs), IgG4-RD cell lines and Usp25 knockout mice, we show that ubiquitin-specific protease 25 (USP25) engages in multiple pathways to regulate fibrotic and inflammatory pathways that are characteristic to IgG4-RD. All together, our data suggests that USP25 is associated with fibrosis, inflammation, and metabolism of IgG4-RD patients, which serves as a potential diagnostic and therapeutic target. Click on the link below for further details 💡 #Genomics #Sequencing #NatureCommunication

Nobel prize medicine 2024: microRNA. Since their discovery in 1993, these very little pieces of mRNA have been implicated in so many regulatory process, from metabolic processes to cancer through their implication in RNA silencing. And from such, many therapeutic options are now available for diseases where options never existed. This represents a significant opportunity in drug development and management of diseases. So far, 6 such agents have been developed and approved, ranging from treating rare metabolic ailments, including hereditary transthyretin amyloidosis (hATTR), acute hepatic porphyria (AHP), primary hyperoxaluria type 1 (PH1), and lowering low-density lipoprotein cholesterol (LDL-C) in subjects with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD). https://lnkd.in/ebY2qAkj https://lnkd.in/e2rhD9AS https://lnkd.in/ev-JbCWg

Redox Medicine 2024: Exploring Emerging Trends, Biomarkers, and Therapeutic Possibilities! #RedoxMedicine2024 this June in Paris will gather experts to discuss the pivotal role of redox processes in medical science, covering a wide range of topics, from drug development to the management of chronic diseases. ➡ Discover how redox science shapes our understanding of disease pathology and innovative treatments. From cancer to cardiovascular diseases and neurodegenerative disorders, explore the impact of oxidative stress and redox signaling. ➡ Learn about emerging therapeutic strategies, including antioxidants, novel drugs, and AI applications. Join Redox Medicine 2024 on June 27 & 28 at Fondation Biermans-Lapôtre, Paris, France! 🔗 Read RMS Press Release: https://lnkd.in/dcGRfDnf 🌐 Visit Website: https://lnkd.in/dkNzFQZU #RedoxMedicineSociety #RedoxMedicine #biomarkers #redoxbiology #redox #antioxidants #innovation #oxidativestress #RedoxResearch

📢 Exciting new research alert! A recent study delves into potential biomarkers for overt hepatic encephalopathy (oHE) in cirrhosis patients. The investigation focuses on neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) as plasma biomarkers. Results suggest that NfL could serve as a diagnostic marker for oHE, showing higher concentrations in ICU patients with oHE compared to controls. Interestingly, NfL concentrations correlated with Model for End-Stage Liver Disease (MELD) scores, indicating its potential as a severity marker. Read more about this groundbreaking research 👉 https://lnkd.in/g3k5DHpm #Hepatology #Research #LiverDisease #Biomarkers.

The type I #interferon (#IFN) pathway has been implicated in the pathogenesis of a number of #rheumatic diseases, including systemic #lupus erythematosus, #Sjögren’s disease, #dermatomyositis, systemic sclerosis, and #rheumatoid #arthritis. The IFN pathway can be targeted at multiple levels, by antibodies directly binding IFNα or -β (e.g. sifalimumab, dazukibart), antibodies blocking the type I IFN receptor (e.g. anifrolumab), and small molecules targeting the intracellular Janus Kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway, also known as JAK inhibitors (e.g. tofacitinib, ruxolitinib, baricitinib). *From: Veldkamp SR, van Wijk F, van Royen-Kerkhof A, Jansen MH. Personalised medicine in juvenile dermatomyositis: From novel insights in disease mechanisms to changes in clinical practice. Best Pract Res Clin Rheumatol. 2024;38(3):101976. 🔗https://lnkd.in/dNQr2Biv

Transformative advancements in targeted lipid nanoparticles (tLNPs) with DSPE-PEG2000-maleimide! DSPE-PEG2000-maleimide helps researchers achieve the ultimate goal of toxicity-free delivery of nucleic acids, and the broader objective of precision medicine, by enabling the formation of LNPs that will specifically conjugate to antibodies and targeting ligands, delivering lipid-based genes to their intended cellular target. In this latest blog, we zoom in on DSPE-PEG2000-maleimide to explore its utility in improving the specificity and therapeutic potency of tLNPs, and how its effect on nucleic acid delivery unlocks new avenues for developing much-needed therapies for a range of human diseases, from cancer to neurological disorders. Today it’s more about personalized therapies, and DSPE-PEG2000-maleimide stands out as a cutting-edge tool with huge potential for the future of medicine. Keep reading our latest blog for more! https://ow.ly/ZiOz30sFnUy #LipidNanoparticles #tLNPs #DSPEPEG2000maleimide #NucleicAcidDelivery #TargetedTherapies #MedicalInnovation #mRNA #HealthcareRevolution #PersonalizedMedicine

Lecanemab is a monoclonal antibody that targets amyloid-beta (Aβ) in the brain, which is implicated in the pathogenesis of Alzheimer's disease. The mode of action of Lecanemab involves the following key steps: 1. Lecanemab specifically binds to soluble Aβ protofibrils. These protofibrils are aggregates of Aβ peptides, which are thought to be particularly toxic to neurons and play a critical role in the development and progression of Alzheimer's disease. 2. By binding to these soluble protofibrils, Lecanemab facilitates their clearance from the brain. This is thought to occur through mechanisms such as microglial-mediated phagocytosis, where the immune cells in the brain remove the antibody-Aβ complexes. 3. Over time, this process leads to a reduction in the accumulation of amyloid plaques in the brain. Amyloid plaques are a hallmark of Alzheimer's disease and are associated with neuronal damage and cognitive decline. 4. Lecanemab's action in reducing amyloid burden may also help modulate neuroinflammatory processes that are exacerbated by the presence of Aβ aggregates, contributing to the neurodegenerative process. Lecanemab aims to slow the progression of Alzheimer's disease by reducing the toxic effects of amyloid-beta in the brain, thereby preserving cognitive function. #lecanemab

Transformative advancements in targeted lipid nanoparticles (tLNPs) with DSPE-PEG2000-maleimide! DSPE-PEG2000-maleimide helps researchers achieve the ultimate goal of toxicity-free delivery of nucleic acids, and the broader objective of precision medicine, by enabling the formation of LNPs that will specifically conjugate to antibodies and targeting ligands, delivering lipid-based genes to their intended cellular target. In this latest blog, we zoom in on DSPE-PEG2000-maleimide to explore its utility in improving the specificity and therapeutic potency of tLNPs, and how its effect on nucleic acid delivery unlocks new avenues for developing much-needed therapies for a range of human diseases, from cancer to neurological disorders. Today it’s more about personalized therapies, and DSPE-PEG2000-maleimide stands out as a cutting-edge tool with huge potential for the future of medicine. Keep reading our latest blog for more! https://ow.ly/LJIJ30sFnU4 #LipidNanoparticles #tLNPs #DSPEPEG2000maleimide #NucleicAcidDelivery #TargetedTherapies #MedicalInnovation #mRNA #HealthcareRevolution #PersonalizedMedicine

https://lnkd.in/dK6PSRMY PRECAME Study: Preventing cardiovascular effects with metformin in obese patients ( Corpori Sano Biotechnology, Brasil 🇧🇷 2002 ): " Insulin resistance sensitiizers or modulators: Therapeutic link between human metabolism, cardiovascular system and cancer " " Specific therapy, to live healthily " " Drug that modulates mitochondrial, endothelial and DNA-telomere function " " A new therapeutic approach in cardiovascular, metabolic and oncological prevention " " Creating a scientific basis for an infinite possibility of future studies and research " " Scientific research that studies the basis of the iceberg of cardiovascular disease " " Through innovative medicines for public health and commited to bringing better health and a better future for patients, translating science and regenerative medicine into medicines that change human lives, as the main objective " " PRECAME Study and Walter's Metabolic Theory, improving the perspective and quality of life of patients " #science #ciencia #medicine #cardiovascular #insulinresistance #diabetes #medicaleducation #obesity #publichealth #prevention #innovation #populationhealth #atherosclerosis #immunology #cellculture #genetherapy #cancer #oncology